The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 29, Issue 7, 2014, Pages 713-719

  Wang, Tao ^a,b   Xiao, Shifu ^a,b   Liu, Yuanyuan ^a,b   Lin, Zhiguang ^a   Su, Ning ^a,b   Li, Xia ^a,b   Li, Guanjun ^a,b   Zhang, Mingyuan ^a   Fang, Yiru ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Alzheimer's disease; amnesia mild cognitive impairment; biomarkers; plasma

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; INTERLEUKIN 10; INTERLEUKIN 6; TAU PROTEIN; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ANAMNESIS; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROLOGIC EXAMINATION; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 84902249775     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.4053     Document Type: Article

References (36)

1. Albert MS, DeKosky ST, Dickson D, et al,. 2011. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 270-279.
2. Angelis P, Scharf S, Mander A, et al,. 1998. Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease. Neurosci Lett 244: 106-108.
3. Angelopoulos P, Agouridaki H, Vaiopoulos H, et al,. 2008. Cytokines in Alzheimer's disease and vascular dementia. Int J Neurosci 118: 1659-1672.
4. Blasko I, Veerhuis R, et al,. 2000. Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human astrocytes. Neurobiol Dis 7: 682-689.
5. Boyle PA, Wilson RS, Aggarwal NT, et al,. 2006. Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 67: 441-445.
6. Doecke JD, Laws SM, Faux NG, et al,. 2012. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 69 (10): 1318-25.
7. Engelhart MJ, Geerlings MI, Meijer J, et al,. 2004. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 61: 668-672.
8. Ferri CP, Prince M, Brayne C, et al,. 2005. Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117.
9. Figurski MJ, Waligõrska T, Toledo J, et al,. 2012. Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. Alzheimers Dement 8 (4): 250-60.
10. Fleisher AS, Chen K, Liu X, et al,. 2011. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 68 (11): 1404-1411.
11. Fleisher AS, Chen K, Quiroz YT, et al,. 2012. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol 11 (12): 1057-1065.
12. Fukumoto H, Tennis M, Locascio JJ, et al,. 2003. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 60: 958-964.
13. Ganguli M, Dodge HH, Shen C, et al,. 2004. Mild cognitive impairment, amnesia type: an epidemiologic study. Neurology 63: 115-121.
14. Hampel H, Blennow K, Shaw LM, et al,. 2010. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 45: 30-40.
15. Jack CR Jr, Albert MS, Knopman DS, et al,. 2011. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 257-262.
16. Katzman R, Zhang MY, Ouang-Ya-Qu, et al,. 1988. A Chinese version of the Mini-Mental State Examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol 41 (10): 971-978.
17. Kelley BJ, Petersen RC,. 2007. Alzheimer's disease and mild cognitive impairment. Neurol Clin 25: 577-609.
18. Leung R, Proitsi P, Simmons A, et al,. 2013. Inflammatory proteins in plasma are associated with severity of Alzheimer's disease. PLoS One 8 (6):e64971. doi: 10.1371/journal.pone.0064971.
19. Licastro F, Pedrini S, Caputo L, et al,. 2000. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol 103: 97-102.
20. Locascio JJ, Fukumoto H, Yap L, et al,. 2008. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol 65: 776-785.
21. Mayeux R, Honig LS, Tang MX, et al,. 2003. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61: 1185-1190.
22. Petersen RC, Doody R, Kurz A, et al,. 2001. Current concepts in mild cognitive impairment. Arch Neurol 58: 1985-1992.
23. Pomara N, Willoughby LM, Sidtis JJ, et al,. 2005. Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am J Geriatr Psychiatry 13: 914-917.
24. Reiman EM, Chen K, Liu X, et al,. 2009. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106 (16): 6820-6825.
25. Rojo LE, Fernandez JA, Maccioni AA, et al,. 2008. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 39: 1-16.
26. Rountree SD, Waring SC, Chan WC, et al,. 2007. Importance of subtle amnesia and nonamnesia deficits in mild cognitive impairment: prognosis and conversion to dementia. Dement Geriatr Cogn Disord 24: 476-482.
27. Schuitemaker A, Dik MG, Veerhuis R, et al,. 2008. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging 30: 1885-1889.
28. Snowdon DA, Kemper SJ, Mortimer JA, et al,. 1996. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA 275: 528-532.
29. Speciale L, Calabrese E, Saresella M, et al,. 2007. Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients. Neurobiol Aging 28: 1163-1169.
30. Strle K, Zhou JH, Shen WH, et al,. 2001. Interleukin-10 in the brain. Crit Rev Immunol 21: 427-449.
31. Sun YX, Minthon L, Wallmark A, et al,. 2003. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dement Geriatr Cogn Disord 16: 136-144.
32. Takeda S, Sato N, Rakugi H, et al,. 2010. Plasma β-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease. Mol Biosyst 6: 1760-1766.
33. Yaffe K, Lindquist K, Penninx BW, et al,. 2003. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 61: 76-80.
34. Yasojima K, Schwab C, McGeer EG, et al,. 2000. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res 887: 80-89.
35. Zhang Y, Xu Y, Nie H, et al,. 2012. Prevalence of dementia and major dementia subtypes in the Chinese populations: a meta-analysis of dementia prevalence surveys, 1980-2010. J Clin Neurosci 19: 1333-1337.
36. Zipser BD, Johanson CE, Gonzalez L, et al,. 2007. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 28: 977-986.